Concert Pharmaceuticals, Inc.

Creating New Possibilities for Patients to Live Their Lives

General Information
Company Name
Concert Pharmaceuticals, Inc.
Founded Year
2006
Location (Offices)
Lexington, United States +1
Founders / Decision Makers
Roger Tung - Founder, President, CEO & Board of Directors Richard Aldrich - Co - Founder Nancy Stuart - COO Robert Zelle - VP Drug Development
Number of Employees
38
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Concert Pharmaceuticals, Inc. - Company Profile

Concert Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2006 and headquartered in the United States. The company's slogan, "Creating New Possibilities for Patients to Live Their Lives," reflects its commitment to developing innovative treatment options. Concert Pharmaceuticals is known for its DCE Platform® (deuterated chemical entity platform) which is utilized to discover small molecule drugs. By selectively incorporating deuterium into known molecules, the company aims to improve their pharmacokinetic or metabolic properties, thus enhancing clinical safety, tolerability, and efficacy.

The company's lead product candidate, currently in late-stage development, targets the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition, Concert Pharmaceuticals is assessing a number of earlier-stage pipeline candidates. Notably, the company secured a significant $66.40M Post-IPO Equity investment on 01 June 2022, with RA Capital Management and BVF Partners as the investors.

Concert Pharmaceuticals' dedication to leveraging innovative scientific platforms and addressing critical unmet medical needs positions it as an attractive investment opportunity in the biotechnology and pharmaceutical industries.

Taxonomy: biopharmaceutical, clinical-stage, DCE Platform, deuterium, precision chemistry, drug development, alopecia areata, autoimmune, dermatological, pharmacokinetic, metabolic properties, pipeline candidates, R&D risk reduction, novel drug candidates

Funding Rounds & Investors of Concert Pharmaceuticals, Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $74.70M - 27 Jan 2020
Post-IPO Debt $30.00M 1
Hercules Capital, investor in Concert Pharmaceuticals, Inc.'s Post-IPO Debt round
12 Jun 2017
Venture Round $4.00M 1
GlaxoSmithKline, investor in Concert Pharmaceuticals, Inc.'s Venture Round round
20 Jun 2011
Series C $37.00M 10
New Leaf Venture Partners, investor in Concert Pharmaceuticals, Inc.'s Series C round Skyline Ventures, investor in Concert Pharmaceuticals, Inc.'s Series C round Flagship Pioneering, investor in Concert Pharmaceuticals, Inc.'s Series C round Three Arch Partners, investor in Concert Pharmaceuticals, Inc.'s Series C round TVM Capital, investor in Concert Pharmaceuticals, Inc.'s Series C round GlaxoSmithKline, investor in Concert Pharmaceuticals, Inc.'s Series C round QVT Financial LP, investor in Concert Pharmaceuticals, Inc.'s Series C round Westfield Capital Management, investor in Concert Pharmaceuticals, Inc.'s Series C round Mediphase Venture Partners, investor in Concert Pharmaceuticals, Inc.'s Series C round
Greylock 		30 Apr 2008
Series A $10.00M 5
Skyline Ventures, investor in Concert Pharmaceuticals, Inc.'s Series A round Three Arch Partners, investor in Concert Pharmaceuticals, Inc.'s Series A round TVM Capital, investor in Concert Pharmaceuticals, Inc.'s Series A round QVT Financial LP, investor in Concert Pharmaceuticals, Inc.'s Series A round
Greylock 		17 Jul 2006

Latest News of Concert Pharmaceuticals, Inc.

View All

No recent news or press coverage available for Concert Pharmaceuticals, Inc..

Similar Companies to Concert Pharmaceuticals, Inc.

View All
ProfoundBio - Similar company to Concert Pharmaceuticals, Inc.
ProfoundBio
Bioneex - Similar company to Concert Pharmaceuticals, Inc.
Bioneex First AI-powered Drug Candidates Marketplace
BlackThorn Therapeutics - Similar company to Concert Pharmaceuticals, Inc.
BlackThorn Therapeutics Pioneering precision medicine for CNS disorders through advanced computational and clinical neuroscience.
Carmot Therapeutics, Inc. - Similar company to Concert Pharmaceuticals, Inc.
Carmot Therapeutics, Inc. Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group.
Nimbus Therapeutics - Similar company to Concert Pharmaceuticals, Inc.
Nimbus Therapeutics We develop breakthrough medicines for patients through precision small molecule design.
Circle Decoration Circle Decoration

Want to dive deeper into Concert Pharmaceuticals, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now